Elicio Therapeutics Past Earnings Performance
Past criteria checks 0/6
Elicio Therapeutics's earnings have been declining at an average annual rate of -21.5%, while the Biotechs industry saw earnings growing at 15% annually.
Key information
-21.5%
Earnings growth rate
-24.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -800.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Elicio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -39 | 12 | 26 |
| 31 Dec 23 | 0 | -35 | 12 | 24 |
| 30 Sep 23 | 0 | -33 | 10 | 22 |
| 30 Jun 23 | 0 | -29 | 8 | 19 |
| 31 Mar 23 | 0 | -29 | 6 | 19 |
| 31 Dec 22 | 0 | -28 | 6 | 18 |
| 30 Sep 22 | 0 | -28 | 5 | 18 |
| 31 Mar 22 | 0 | -27 | 7 | 18 |
| 31 Dec 21 | 0 | -26 | 8 | 18 |
| 31 Mar 21 | 0 | -19 | 4 | 15 |
| 31 Dec 20 | 0 | -16 | 3 | 13 |
Quality Earnings: ELTX is currently unprofitable.
Growing Profit Margin: ELTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ELTX is unprofitable, and losses have increased over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare ELTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ELTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ELTX has a negative Return on Equity (-800.68%), as it is currently unprofitable.